Sagespring Wealth Partners LLC Acquires Shares of 19,344 Novo Nordisk A/S (NYSE:NVO)

Sagespring Wealth Partners LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,344 shares of the company's stock, valued at approximately $1,664,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. M. Kulyk & Associates LLC lifted its stake in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares during the last quarter. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the last quarter. Tradewinds Capital Management LLC lifted its position in Novo Nordisk A/S by 2.6% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after acquiring an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC increased its position in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock worth $1,987,000 after purchasing an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 4.2% during the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after purchasing an additional 126 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $4.43 during trading hours on Thursday, reaching $58.45. The stock had a trading volume of 19,208,812 shares, compared to its average volume of 5,903,071. The firm has a market capitalization of $262.30 billion, a PE ratio of 17.75, a PEG ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a twelve month low of $57.36 and a twelve month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock's 50 day moving average is $76.55 and its 200 day moving average is $92.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is 49.54%.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVO shares. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.